Abstract 547P
Background
Immunotherapy is now standard of care in advanced/metastatic lung cancer patients either in first line alone or in combination with chemotherapy, also in subsequent lines. Here, we presenting real world outcome with immunotherapy in lung cancer patients from India.
Methods
We performed an analysis of prospectively collected data of patients with advanced/metastatic lung cancer treated at a single academic cancer centre in India. The patient’s demographic data, treatment details, toxicity and response to treatment captured from electronic medical record of each patient. Data was analysed for safety and survival outcome.
Results
From August 2015 to September 2021, 164 eligible patients were included in this study. Median age at presentation was 59 year (range 21 year to 86 year). 82% (n=134) were male and 18% (n=34) were female (M: F 4.5:1). At presentation, 73% (n=118) were ECOG PS 0 or 1, 14.5% (n=24) were ECOG PS 2, and 12.5% (n=22) were ECOG PS 3 or 4. Out of 164, 33% (n = 54), received immunotherapy drug in first line, 46% (n = 76) in second line, 21% (n = 34) in third line and beyond. 65% (n=106) received Nivolumab, 26.5% (n=44) received Pembrolizumab, 8.5% (n=14) received Atezolizumab. Median progression free survival and median overall survival was 5 months (95% CI 3.5 to 6.5 month) and 10 months (95% CI 7.3 to 12.7 month) respectively. Overall, 3-year PFS and OS rate is 5% and 23%. Fatigue was most common seen in 15% patients, hyponatremia in 5.3%, anorexia in 2.4%. Among immune-related toxicity- pneumonitis was most common seen in 4.8%, followed by hypothyroidism in 3.8%, transaminitis and nephritis in 1.9% each, skin rash, colitis, and encephalitis in 1.4% each, adrenal insufficiency and hypophysitis in 1% each seen.
Conclusions
In real world, immunotherapy having clinically significant benefit on survival in advanced/metastatic lung cancer patients with acceptable safety profile including patients with borderline performance status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract